Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France

Objective: To update the health economic evaluation of pirfenidone in the treatment of idiopathic pulmonary fibrosis (IPF) compared to all available alternatives strategies (Best supportive care – BSC and nintedanib), based on a cost-utility model previously validated by the CEESP’s (French Committe...

Descripción completa

Detalles Bibliográficos
Autores principales: Clay, Emilie, Cristeau, Olivier, Chafaie, Romain, Pinta, Alexandrina, Mazaleyrat, Benjamin, Cottin, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598518/
https://www.ncbi.nlm.nih.gov/pubmed/31275535
http://dx.doi.org/10.1080/20016689.2019.1626171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598518/
https://www.ncbi.nlm.nih.gov/pubmed/31275535
http://dx.doi.org/10.1080/20016689.2019.1626171

Ejemplares similares